174 related articles for article (PubMed ID: 37210448)
41. Safety and feasibility of minimally invasive gastrectomy during the early introduction in the Netherlands: short-term oncological outcomes comparable to open gastrectomy.
Brenkman HJF; Ruurda JP; Verhoeven RHA; van Hillegersberg R
Gastric Cancer; 2017 Sep; 20(5):853-860. PubMed ID: 28185027
[TBL] [Abstract][Full Text] [Related]
42. Transatlantic registries of pancreatic surgery in the United States of America, Germany, the Netherlands, and Sweden: Comparing design, variables, patients, treatment strategies, and outcomes.
Mackay TM; Gleeson EM; Wellner UF; Williamsson C; Busch OR; Groot Koerkamp B; Keck T; van Santvoort HC; Tingstedt B; Pitt HA; Besselink MG;
Surgery; 2021 Feb; 169(2):396-402. PubMed ID: 32868111
[TBL] [Abstract][Full Text] [Related]
43. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection.
Riediger H; Makowiec F; Fischer E; Adam U; Hopt UT
J Gastrointest Surg; 2006; 10(8):1106-15. PubMed ID: 16966029
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
45. Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma.
Nussbaum DP; Adam MA; Youngwirth LM; Ganapathi AM; Roman SA; Tyler DS; Sosa JA; Blazer DG
Ann Surg Oncol; 2016 Mar; 23(3):1026-33. PubMed ID: 26542590
[TBL] [Abstract][Full Text] [Related]
46. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
47. Pancreatoduodenectomy with venous resection for ductal adenocarcinoma rarely achieves complete (R0) resection.
Kleive D; Labori KJ; Line PD; Gladhaug IP; Verbeke CS
HPB (Oxford); 2020 Jan; 22(1):50-57. PubMed ID: 31186199
[TBL] [Abstract][Full Text] [Related]
48. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival.
Fatima J; Schnelldorfer T; Barton J; Wood CM; Wiste HJ; Smyrk TC; Zhang L; Sarr MG; Nagorney DM; Farnell MB
Arch Surg; 2010 Feb; 145(2):167-72. PubMed ID: 20157085
[TBL] [Abstract][Full Text] [Related]
49. Positive Resection Margins Detected by Standardized Study of a Pancreaticoduodenectomy Sample: Is There Any Real Impact on Long-term Survival?
Di Martino M; Muñoz de Nova JL; Guijarro Rojas M; Alday Muñoz E; Martín-Pérez E
Cir Esp (Engl Ed); 2020 Mar; 98(3):127-135. PubMed ID: 31784034
[TBL] [Abstract][Full Text] [Related]
50. Resection of portovenous structures to obtain microscopically negative margins during pancreaticoduodenectomy for pancreatic adenocarcinoma is worthwhile.
Toomey P; Hernandez J; Morton C; Duce L; Farrior T; Villadolid D; Ross S; Rosemurgy A
Am Surg; 2009 Sep; 75(9):804-9; discussion 809-10. PubMed ID: 19774952
[TBL] [Abstract][Full Text] [Related]
51. Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience.
Petrou A; Soonawalla Z; Silva MA; Manzelli A; Moris D; Tabet PP; Friend P
J BUON; 2016; 21(4):874-882. PubMed ID: 27685908
[TBL] [Abstract][Full Text] [Related]
52. [Surgery for pancreatic cancer].
Welsch T; Büchler MW; Schmidt J
Z Gastroenterol; 2008 Dec; 46(12):1393-403. PubMed ID: 19053009
[TBL] [Abstract][Full Text] [Related]
53. Oncological outcome of laparoscopically assisted pancreatoduodenectomy for ductal adenocarcinoma in a retrospective cohort study.
Kuesters S; Chikhladze S; Makowiec F; Sick O; Fichtner-Feigl S; Hopt UT; Wittel UA
Int J Surg; 2018 Jul; 55():162-166. PubMed ID: 29807171
[TBL] [Abstract][Full Text] [Related]
54. The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy.
Watson MD; Thompson KJ; Musselwhite LW; Hwang JJ; Baker EH; Martinie JB; Vrochides D; Iannitti DA; Ocuin LM
Am J Surg; 2021 Jul; 222(1):159-166. PubMed ID: 33121658
[TBL] [Abstract][Full Text] [Related]
55. Frozen section analysis of the pancreatic margin during pancreaticoduodenectomy for cancer: Does extending the resection to obtain a secondary R0 provide a survival benefit? Results of a systematic review.
Petrucciani N; Nigri G; Debs T; Giannini G; Sborlini E; Antolino L; Aurello P; D'Angelo F; Gugenheim J; Ramacciato G
Pancreatology; 2016; 16(6):1037-1043. PubMed ID: 27697467
[TBL] [Abstract][Full Text] [Related]
56. [Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma].
Motoi F; Kawaguchi K; Aoki T; Kudo K; Yabuuchi S; Fukase K; Mizuma M; Sakata N; Otsutomo S; Morikawa T; Hayashi H; Nakagawa K; Okada T; Yoshida H; Naitoh T; Katayose Y; Egawa S; Unno M
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1632-6. PubMed ID: 24393872
[TBL] [Abstract][Full Text] [Related]
57. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.
Noda Y; Pisuchpen N; Mercaldo ND; Sekigami Y; Michelakos T; Parakh A; Wo JY; Qadan M; Ferrone C; Lillemoe KD; Ryan DP; Clark JW; Fernandez-Del Castillo C; Hong TS; Kambadakone AR
Eur Radiol; 2022 Apr; 32(4):2470-2480. PubMed ID: 34665317
[TBL] [Abstract][Full Text] [Related]
58. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
[TBL] [Abstract][Full Text] [Related]
59. Margin status impacts survival after pancreaticoduodenectomy but negative margins should not be pursued.
Mathur A; Ross SB; Luberice K; Kurian T; Vice M; Toomey P; Rosemurgy AS
Am Surg; 2014 Apr; 80(4):353-60. PubMed ID: 24887665
[TBL] [Abstract][Full Text] [Related]
60. Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma.
Jamiyan T; Shiraki T; Kurata Y; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2020 Jun; 18(1):137. PubMed ID: 32571348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
